StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)

Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –

ImmuCell net income

Net income is the profit left for shareholders after every expense, interest and tax.

ImmuCell's net income for the twelve months ending Jun 30, 2026 was $787.37K, down 55.3% year over year. For fiscal 2025 it was -$1.04M. The highest annual figure on record is $1.21M in fiscal 2015.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.04M–
FY2024Dec 31, 2024-$2.16M–
FY2023Dec 31, 2023-$5.77M–
FY2022Dec 31, 2022-$2.49M–
FY2021Dec 31, 2021-$78.29K–
FY2020Dec 31, 2020-$1.02M–
FY2019Dec 31, 2019-$1.30M–
FY2018Dec 31, 2018-$2.32M–
FY2017Dec 31, 2017-$168.15K-133.1%
FY2016Dec 31, 2016$508.45K-58.1%
FY2015Dec 31, 2015$1.21M–
FY2014Dec 31, 2014-$167.16K-242.4%
FY2013Dec 31, 2013$117.40K+31.2%
FY2012Dec 31, 2012$89.51K–
FY2011Dec 31, 2011-$409.51K–
FY2010Dec 31, 2010-$384.68K–
FY2009Dec 31, 2009-$216.49K–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.83M+265.6%
Q1 FY2026Mar 31, 2026$1.94M+34.2%
Q4 FY2025Dec 31, 2025-$2.85M-653.7%
Q3 FY2025Sep 30, 2025-$139.75K–
Q2 FY2025Jun 30, 2025$501.88K–
Q1 FY2025Mar 31, 2025$1.45M–
Q4 FY2024Dec 31, 2024$514.56K–
Q3 FY2024Sep 30, 2024-$701.69K–
Q2 FY2024Jun 30, 2024-$1.53M–
Q1 FY2024Mar 31, 2024-$437.87K–
Q4 FY2023Dec 31, 2023-$1.14M–
Q3 FY2023Sep 30, 2023-$940.00K–
Q2 FY2023Jun 30, 2023-$1.38M–
Q1 FY2023Mar 31, 2023-$2.32M-551.0%
Q4 FY2022Dec 31, 2022-$1.67M-2349.8%
Q3 FY2022Sep 30, 2022-$655.08K-543.3%
Q2 FY2022Jun 30, 2022-$684.15K-584.8%
Q1 FY2022Mar 31, 2022$513.29K–
Q4 FY2021Dec 31, 2021$74.13K-60.7%
Q3 FY2021Sep 30, 2021$147.76K–
Q2 FY2021Jun 30, 2021$141.11K–
Q1 FY2021Mar 31, 2021-$441.30K–
Q4 FY2020Dec 31, 2020$188.83K–
Q3 FY2020Sep 30, 2020-$322.89K–
Q2 FY2020Jun 30, 2020-$765.79K–
Q1 FY2020Mar 31, 2020-$122.27K-184.6%
Q4 FY2019Dec 31, 2019-$310.45K–
Q3 FY2019Sep 30, 2019-$502.54K–
Q2 FY2019Jun 30, 2019-$627.16K–
Q1 FY2019Mar 31, 2019$144.56K–
Q4 FY2018Dec 31, 2018-$1.05M–
Q3 FY2018Sep 30, 2018-$249.96K–
Q2 FY2018Jun 30, 2018-$798.36K–
Q1 FY2018Mar 31, 2018-$221.12K-137.8%
Q4 FY2017Dec 31, 2017-$194.66K-742.7%
Q3 FY2017Sep 30, 2017-$339.35K-1073.2%
Q2 FY2017Jun 30, 2017-$218.39K–
Q1 FY2017Mar 31, 2017$584.24K–
Q4 FY2016Dec 31, 2016$30.29K–
Q3 FY2016Sep 30, 2016$34.87K–

More ImmuCell figures

See a number that looks wrong?